MRKMerck Sharp & Dohme LLCFinished
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Melanoma
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 1/2
- Patients
- 56 (final count)
- Started
- May 3, 2021
- Main results expected
- Oct 17, 2025
- Fully finished
- Oct 17, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants who experience an adverse event (AE)
Measured over: Up to ~28 months
Percentage of participants who discontinue study treatment due to an AE
Measured over: Up to ~24 months
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Measured over: Up to ~30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-17, no fading
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04700072 · record last updated 2025-10-28 · checked 2026-11-09 15:47 UTC